Annals of Hematology

, Volume 91, Issue 11, pp 1721–1729 | Cite as

Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases

  • Xiaoyang Li
  • Weina Shen
  • Junning Cao
  • Jianmin Wang
  • Fangyuan Chen
  • Chun Wang
  • Shanhua Zou
  • Boyong Shen
  • Ren Zhao
  • Junmin Li
  • Zhixiang Shen
Original Article


Gastrointestinal diffuse large B cell lymphoma (DLBCL) is a common subtype of extranodal lymphoma. There has been uncertainty about the clinical efficacy of combination therapy (surgery and chemotherapy) for gastrointestinal DLBCL. We retrospectively analyzed 114 patients with newly diagnosed gastrointestinal DLBCL from six medical centers. We evaluated four groups based on whether they were treated with or without surgery as the initial treatment for DLBCL, followed by either a regimen with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) or CHOP with rituximab (R-CHOP). For all patients, treatment with R-CHOP resulted in significantly greater overall survival (OS; 93.2 vs 74.5 %, p = 0.008) and progression-free survival (89.8 % vs 72.7, p = 0.029). Tumor resection did not improve OS (84.0 vs 85.0 %, for surgery and chemotherapy alone, respectively, p = 0.980). However, for younger patients, overall survival was greater (p = 0.005) for patients treated with surgery plus chemotherapy (83.9 %) than for patients treated with chemotherapy alone (40.0 %). Elevated serum lactate dehydrogenase level (p = 0.004) and performance status (Eastern Cooperative Oncology Group; p = 0.003) were independent predictors of survival in patients with gastrointestinal DLBCL. Stage-modified IPI was recognized as the best prognostic tool. There were significant differences among patients with low-risk, intermediate-risk, and high-risk groups in 50-month OS (94.2 vs 84.0 vs 66.7 %, p = 0.008). The results of this large-scale study suggest that R-CHOP regimen is the first-line treatment for gastrointestinal DLBCL. The benefit of surgery for these patients remains controversial. Further prospective analyses are warranted.


Gastrointestinal DLBCL Rituximab Surgery resection Predict prognosis factor Overall survival 



We are indebted to Dr. Chenli Zhang and Dr. Jing Sun, Department of Gastroenterology, Shanghai Ruijin Hospital for their contribution to the collection of patient data. We would like to thank the doctors from Shanghai Lymphoma Research Group for their contribution to this study. We thank all the pathologists, oncologists, radiologists, surgeons, and nurses who contributed.

Disclosure statement

The authors declare no conflict of interest.


  1. 1.
    Jemal A, Siegel R, Ward EM, Thun MJ (2008) Cancer facts and figures. Accessed 19 Jun 2008.
  2. 2.
    Xiao-long JI, Ming-shi SHEN (1999) Extranodal lymphoma in China: an analysis of 943 cases. Chin J Canc 18(5):570–572Google Scholar
  3. 3.
    Freeman C, Berg JW, Cutler SJ (1972) Occurrence and prognosis of extranodal lymphomas. Cancer 29:252–260PubMedCrossRefGoogle Scholar
  4. 4.
    Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rübe C et al (2001) Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 19:3861–3873PubMedGoogle Scholar
  5. 5.
    Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C, Xiros N, Economopoulos T et al (2006) Primary gastrointestinal non-Hodgkin’s lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma 47:2140–2146PubMedCrossRefGoogle Scholar
  6. 6.
    Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116(12):2040–2045PubMedCrossRefGoogle Scholar
  7. 7.
    Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O’Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD et al (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23(22):5027–5033PubMedCrossRefGoogle Scholar
  8. 8.
    Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121–3127PubMedCrossRefGoogle Scholar
  9. 9.
    Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z (2012) Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Ann Hematol 91(6):837–845PubMedCrossRefGoogle Scholar
  10. 10.
    Binn M, Ruskoné-Fourmestraux A, Lepage E, Haioun C, Delmer A, Aegerter P, Lavergne A, Guettier C, Delchier JC (2003) Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Ann Oncol 14(12):1751–1757PubMedCrossRefGoogle Scholar
  11. 11.
    Huang J, Jiang W, Xu R, Huang H, Lv Y, Xia Z, Sun X, Guan Z, Lin T, Li Z (2010) Primary gastric non-Hodgkin’s lymphoma in Chinese patients: clinical characteristics and prognostic factors. BMC Cancer 10:358PubMedCrossRefGoogle Scholar
  12. 12.
    DAmore F, Christensen BE, Brincker H, Pedersen NT, Thorling K, Hastrup J (1991) Clinico-pathological features and prognostic factors in extranodal non-Hodgkin's lymphomas. Eur J Cancer 27:1201–1208CrossRefGoogle Scholar
  13. 13.
    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244PubMedGoogle Scholar
  14. 14.
    Aisenberg AC (1995) Coherent view of non-Hodgkin’s lymphoma. J Clin Oncol 13:2656–2675PubMedGoogle Scholar
  15. 15.
    Zucca R, Conconi A, Roggero R (2000) Non-gastric MALT lymphoma: a survey of 369 European patients—The International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 11:99Google Scholar
  16. 16.
    Herrmann R, Panahon AM, Barcos MP, Walsh D, Stutzman L (1980) Gastrointestinal involvement in non-Hodgkin's lymphoma. Cancer 46:215–222PubMedCrossRefGoogle Scholar
  17. 17.
    Avilés A, Nambo MJ, Neri N, Huerta-Guzmán J, Cuadra I, Alvarado I, Castañeda C, Fernández R, González M (2004) The role of surgery in primary gastric lymphoma: results of a controlled clinical trial. Ann Surg 240(1):44–50PubMedCrossRefGoogle Scholar
  18. 18.
    Tanaka T, Shimada K, Yamamoto K, Hirooka Y, Niwa Y, Sugiura I, Kitamura K, Kosugi H, Kinoshita T, Goto H, Nakamura S (2012) Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan. Ann Hematol 91(3):383–390PubMedCrossRefGoogle Scholar
  19. 19.
    Aviles A, Castaneda C, Cleto S, Neri N, Huerta-Guzman J, Gonzalez M, Nambo MJ (2009) Rituximab and chemotherapy in primary gastric lymphoma. Cancer Biother Radiopharm 24(1):25–28PubMedCrossRefGoogle Scholar
  20. 20.
    Gutiérrez-García G, Colomo L, Villamor N, Arenillas L, Martínez A, Cardesa T, García-Herrera A, Setoain X, Rodríguez S, Ghita G, Abrisqueta P, Giné E et al (2010) Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 51(7):1225–1232PubMedCrossRefGoogle Scholar
  21. 21.
    Witzens-Harig M, Reiz M, Heiß C, Benner A, Hensel M, Neben K, Dreger P, Kraemer A, Anthony DHo (2009) Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial. Ann Hematol 88(1):51–57PubMedCrossRefGoogle Scholar
  22. 22.
    Huang BT, Zeng QC, Yu J, Xiao Z, Li BS, Zhang CL, Ji HB (2012) How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience. J Cancer Res Clin Oncol 138(1):125–132PubMedCrossRefGoogle Scholar
  23. 23.
    Morton JE, Leyland MJ, Vaughan Hudson G, Vaughan Hudson B, Anderson L, Bennett MH, MacLennan KA (1993) Primary gastrointestinal non- Hodgkin’s lymphoma: a review of 175 British National Lymphoma Investigation cases. Br J Cancer 67:776–782PubMedCrossRefGoogle Scholar
  24. 24.
    Salles G, Herbrecht R, Tilly H, Berger F, Brousse N, Gisselbrecht C, Coiffier B (1991) Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d’Etude des Lymphomes Aggressifs. Am J Med 90:77–84PubMedCrossRefGoogle Scholar
  25. 25.
    Willich NA, Reinartz G, Horst EJ, Delker G, Reers B, Hiddemann W, Tiemann M, Parwaresch R, Grothaus-Pinke B, Kocik J, Koch P (1999) Therapeutic management of stage I-II high grade primary gastric lymphoma. Oncology 56:274–281CrossRefGoogle Scholar
  26. 26.
    Xia ZG, Xu ZZ, Zhao WL, Zhao SQ, Ding F, Chen Y, Chen QS, Zheng Y, Zhu Q, Hu JP, Shen ZX, Li JM (2010) The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. Ann Hematol 89(2):171–177PubMedCrossRefGoogle Scholar
  27. 27.
    Hermine O, Haioun C, Lepage E, d’Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 87:265–272PubMedGoogle Scholar
  28. 28.
    Horning SJ, Weller E, Kim K, Earle JD, O'Connell MJ, Habermann TM, Glick JH (2004) Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22(15):3032–3038PubMedCrossRefGoogle Scholar
  29. 29.
    Ang MK, Hee SW, Quek R, Yap SP, Loong S, Tan L, Tao M, Lim ST (2009) Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis. Ann Hematol 88(5):417–424PubMedCrossRefGoogle Scholar
  30. 30.
    Mok TS, Steinberg J, Chan AT, Yeo WM, Hui P, Leung TW, Johnson P (1998) Application of the international prognostic index in a study of Chinese patients with non-Hodgkin’s lymphoma and a high incidence of primary extranodal lymphoma. Cancer 82(12):2439–2448PubMedCrossRefGoogle Scholar
  31. 31.
    Cortelazzo S, Rossi A, Roggero F, Oldani E, Zucca E, Tondini C, Ambrosetti A, Pasini F, Pinotti G, Bertini M, Vitolo U, Busetto M et al (1999) Stage-modified International Prognostic Index effectively predicts outcome of localized primary gastric diffuse large cell lymphoma. Ann Oncol 10:1433–1440PubMedCrossRefGoogle Scholar
  32. 32.
    Cortelazzo S, Rossi A, Oldani E, Motta T, Giardini R, Zinzani PL, Zucca E, Gomez H, Ferreri AJ, Pinotti G, Chini C, Devizzi L et al (2002) The Modified International Prognostic Index can predict the outcome of localized intestinal lymphoma of both extranodal marginal B-cell and diffuse large B-cell lymphoma. Br J Haematol 118:218–228PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Xiaoyang Li
    • 1
  • Weina Shen
    • 1
  • Junning Cao
    • 2
  • Jianmin Wang
    • 3
  • Fangyuan Chen
    • 4
  • Chun Wang
    • 5
  • Shanhua Zou
    • 6
  • Boyong Shen
    • 7
  • Ren Zhao
    • 8
  • Junmin Li
    • 1
  • Zhixiang Shen
    • 1
  1. 1.Department of Hematology, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiPeople’s Republic of China
  2. 2.Department of Medical OncologyFudan University Shanghai Cancer CenterShanghaiChina
  3. 3.Changhai HospitalShanghaiChina
  4. 4.Renji HospitalShanghaiChina
  5. 5.Shanghai No.1 People’s HospitalShanghaiChina
  6. 6.Zhongshan HospitalShanghaiChina
  7. 7.Institute of Digestive Surgery, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiChina
  8. 8.Department of General Surgery, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiChina

Personalised recommendations